Generation Bio Co. (NASDAQ:GBIO – Get Free Report) shares traded up 13.9% on Monday . The stock traded as high as $0.45 and last traded at $0.44. 1,999,892 shares changed hands during mid-day trading, an increase of 381% from the average session volume of 416,001 shares. The stock had previously closed at $0.39.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Generation Bio in a research report on Thursday, May 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Generation Bio in a research report on Monday, March 17th.
Get Our Latest Analysis on GBIO
Generation Bio Trading Up 13.9%
The firm has a market capitalization of $29.50 million, a PE ratio of -0.41 and a beta of 2.59. The firm has a 50-day moving average of $0.37 and a two-hundred day moving average of $0.54.
Generation Bio (NASDAQ:GBIO – Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Generation Bio had a negative return on equity of 75.84% and a negative net margin of 292.92%. The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $1.70 million. Equities research analysts expect that Generation Bio Co. will post -1.75 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new stake in shares of Generation Bio during the fourth quarter valued at about $25,000. JPMorgan Chase & Co. grew its stake in shares of Generation Bio by 74.9% during the fourth quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock valued at $316,000 after acquiring an additional 127,513 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Generation Bio by 62.0% during the fourth quarter. Renaissance Technologies LLC now owns 962,959 shares of the company’s stock valued at $1,021,000 after acquiring an additional 368,659 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Generation Bio during the fourth quarter valued at about $77,000. Finally, Deutsche Bank AG grew its stake in shares of Generation Bio by 688.7% during the fourth quarter. Deutsche Bank AG now owns 184,173 shares of the company’s stock valued at $195,000 after acquiring an additional 160,822 shares in the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.
About Generation Bio
(Get Free Report)
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
See Also
Receive News & Ratings for Generation Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Generation Bio and related companies with MarketBeat.com’s FREE daily email newsletter.
